HOME >> MEDICINE >> NEWS
Drug-eluting stent controversy explored in the American Heart Hospital Journal

cardiology and are here to stay. Recognizing that they are different from bare metal stents, it is prudent to exercise caution with these devices and avoid using them in patients in whom dual antiplatelet therapy, a common practice used to reduce blood clotting, is unlikely or impossible.

Dr. Peter Fitzgerald of Stanford University Medical Center, who writes with his colleagues, Drs. Shimohama and Honda of the Center for Cardiovascular Technology, offers his view of the future of DESs. While first generation DESs place great emphasis on efficacy, long-term safety issues have arisen, making DESs stand in an exquisite balance among occasionally conflicting effects. Careful reexamination of research findings, as well as redefinition of safe and effective outcomes, will lead future stent technology in the optimal direction.


'"/>

Contact: Sean Wagner
swagner@bos.blackwellpublishing.com
781-388-8550
Blackwell Publishing Ltd.
8-Aug-2007


Page: 1 2

Related medicine news :

1. Drug-eluting and absorbable stents push interventional frontiers
2. Drug-eluting stents outperform radiation treatment for coronary restenosis in bare metal stents
3. Drug-eluting stents may cause allergic reactions
4. Drug-eluting stents successfully treat vein-graft disease
5. SCAI news: Drug-eluting stents prove mettle in heart attack patients
6. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
7. New study counts the economic cost of persistent pain in Australia
8. New biodegradable magnesium stents for coronary arteries
9. Emory University researchers find persistent and severe asthma associated with obesity
10. Persistent smokers may have higher risk to become depressed than never smokers
11. Long-term anti-clotting therapy sweetens stenting outcomes in diabetic patients

Post Your Comments:
(Date:5/21/2013)... Artisan Business Group is to ... Conference in Long Beach, California on May 30, ... alternative finance through EB-5 immigrant investors program. The ... economic information, and updates to project developers, regional ... EB-5 industry. , "Our goal is to ...
(Date:5/21/2013)... 21, 2013 According to a May 13, ... Use of Botox,” Botox injections have become the ... in 2002 (Go to goo.gl/8iYbD). Although it is mostly associated ... men. The injection makes facial wrinkles less visible by paralyzing ... for about three months. This means that people who are ...
(Date:5/21/2013)... Focus, a non-profit organization striving to improve the living ... Corridor region, is releasing results for its 2013 Creative ... May 23rd at 10:30 a.m. The survey follows ... The survey is a critical component to the organizations’ ... and retain people of diverse backgrounds, cultures and beliefs ...
(Date:5/21/2013)... (May 21, 2013) A paper recently published in ... co-written by physicians and scientists at the University of ... risk factor for pulmonary fibrosis can be used to ... , Researchers looked at a fairly common variant of ... component of the mucous produced by the bronchial tubes. ...
(Date:5/21/2013)... Brazilian funding agency for scientific and technological research So ... So Paulo, announced an investment estimated in US$ 680 ... (RIDCs) for a period of up to eleven years, ... 7. , Funding for the 17 RIDCs will ... faculty, technicians, support personnel, and infrastructure). Host institutions will ...
Breaking Medicine News(10 mins):Health News:Artisan Business Group to Host EB-5 Investment Conference in Long Beach, California 2Health News:Botox – Is the World’s Most Popular Cosmetic Procedure Safe? 2Health News:Diversity Focus Announces Results from 2013 Creative Corridor Survey at News Conference on Thursday, May 23rd at 10:30 a.m. 2Health News:Researchers find genetic risk factor for pulmonary fibrosis 2Health News:Research at the cutting edge of knowledge 2
(Date:5/21/2013)... , May 21, 2013 /PRNewswire/ ... VRX ) (TSX: VRX) ... directors nominated at its 2013 annual ... results of the vote for the ... below:  NameForWithheldRonald H. Farmer235,731,9341,964,748Robert A. Ingram233,865,8763,830,806Theo ...
(Date:5/21/2013)... , May 21, 2013   Regulus Therapeutics ... leading the discovery and development of innovative medicines targeting ... , Ph.D., Chief Operating Officer and Executive Vice ... Deutsche Bank 38th Annual Healthcare Conference on Wednesday, May ... being held at the Westin Boston Waterfront Hotel. ...
(Date:5/21/2013)... , May 21, 2013 RenovoRx ( ... 2013 TiE50 "Top Startup" Award at TiEcon 2013, the ... strong management team and quality of entrepreneurial ideas. RenovoRx ... the Santa Clara Convention Center. ... influential list of the most enterprising startup companies across ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces 2013 Annual Meeting Results 2Regulus to Present at Deutsche Bank 38th Annual Healthcare Conference 2RenovoRx Named Winner of 2013 TiE50 "Top Startup" 2
Cached News: